About Repligen Corporation (NASDAQ:RGEN)
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:RGEN
- CUSIP: 75991610
- Web: www.repligen.com
- Market Cap: $1.26473 billion
- Outstanding Shares: 37,356,000
- 50 Day Moving Avg: $40.45
- 200 Day Moving Avg: $39.77
- 52 Week Range: $26.16 - $46.81
Sales & Book Value:
- Trailing P/E Ratio: 74.21
- Foreward P/E Ratio: 51.24
- P/E Growth: 2.59
- Annual Revenue: $113.32 million
- Price / Sales: 12.50
- Book Value: $5.60 per share
- Price / Book: 6.77
- EBITDA: $29.54 million
- Net Margins: 15.61%
- Return on Equity: 9.90%
- Return on Assets: 5.93%
- Debt-to-Equity Ratio: 0.51%
- Current Ratio: 11.87%
- Quick Ratio: 10.29%
- Average Volume: 377,043 shs.
- Beta: 1.18
- Short Ratio: 11.59
Frequently Asked Questions for Repligen Corporation (NASDAQ:RGEN)
What is Repligen Corporation's stock symbol?
Repligen Corporation trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen Corporation's earnings last quarter?
Repligen Corporation (NASDAQ:RGEN) released its quarterly earnings data on Thursday, August, 3rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.05. The business earned $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. Repligen Corporation's revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.16 EPS. View Repligen Corporation's Earnings History.
When will Repligen Corporation make its next earnings announcement?
What guidance has Repligen Corporation issued on next quarter's earnings?
Repligen Corporation issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $0.57-0.62 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $138-144 million, compared to the consensus revenue estimate of $128.09 million.
Where is Repligen Corporation's stock going? Where will Repligen Corporation's stock price be in 2017?
4 brokerages have issued 12-month target prices for Repligen Corporation's stock. Their forecasts range from $40.00 to $50.00. On average, they anticipate Repligen Corporation's share price to reach $46.00 in the next twelve months. View Analyst Ratings for Repligen Corporation.
Who are some of Repligen Corporation's key competitors?
Some companies that are related to Repligen Corporation include Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), CorMedix (CRMD), Check-Cap (CHEK), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Repligen Corporation's key executives?
Repligen Corporation's management team includes the folowing people:
- Karen A. Dawes, Independent Chairperson of the Board
- Tony John Hunt, President, Chief Executive Officer, Director
- Jon K. Snodgres, Chief Financial Officer
- Howard Benjamin Ph.D., Vice President - Business Development
- Nicolas M. Barthelemy, Independent Director
- Glenn L. Cooper M.D., Independent Director
- John G. Cox, Independent Director
- Glenn P. Muir, Independent Director
- Thomas F. Ryan Jr., Independent Director
Who owns Repligen Corporation stock?
Repligen Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include
EDDLEMAN ROY T
(11.00%) and Assenagon Asset Management S.A. (0.21%). Company insiders that own Repligen Corporation stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen Corporation.
Who bought Repligen Corporation stock? Who is buying Repligen Corporation stock?
How do I buy Repligen Corporation stock?
Shares of Repligen Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen Corporation's stock price today?
MarketBeat Community Rating for Repligen Corporation (NASDAQ RGEN)MarketBeat's community ratings are surveys of what our community members think about Repligen Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Repligen Corporation stock can currently be purchased for approximately $37.92.
Consensus Ratings for Repligen Corporation (NASDAQ:RGEN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$46.00 (21.31% upside)|Consensus Price Target History for Repligen Corporation (NASDAQ:RGEN)
Analysts' Ratings History for Repligen Corporation (NASDAQ:RGEN)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/19/2017||Jefferies Group LLC||Reiterated Rating||Hold||$40.00||N/A|
|10/2/2017||First Analysis||Upgrade||Equal Weight -> Overweight||$47.00||Medium|
|7/21/2017||William Blair||Initiated Coverage||Outperform -> Outperform||Low|
|6/23/2017||Janney Montgomery Scott||Boost Price Target||$42.00 -> $47.00||High|
|2/22/2016||Craig Hallum||Initiated Coverage||Buy||N/A|
Earnings History for Repligen Corporation (NASDAQ:RGEN)Earnings History by Quarter for Repligen Corporation (NASDAQ RGEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||$0.15||$0.20||$31.72 million||$32.40 million||View||Listen|
|5/4/2017||3/31/2017||$0.13||$0.15||$29.28 million||$30.59 million||View||Listen|
|2/22/2017||Q416||$0.07||$0.08||$24.05 million||$25.60 million||View||Listen|
|11/3/2016||Q316||$0.08||$0.08||$24.39 million||$24.70 million||View||N/A|
|8/4/2016||Q216||$0.13||$0.16||$24.75 million||$29.20 million||View||N/A|
|5/5/2016||Q116||$0.10||$0.12||$22.54 million||$25.10 million||View||N/A|
|2/25/2016||Q415||$0.07||$0.07||$19.84 million||$21.40 million||View||Listen|
|11/5/2015||Q315||$0.08||$0.08||$20.50 million||$19.80 million||View||N/A|
|8/6/2015||Q215||$0.08||$0.11||$20.05 million||$21.50 million||View||N/A|
|5/7/2015||Q115||$0.07||$0.09||$18.20 million||$20.82 million||View||N/A|
|3/13/2015||Q414||$0.04||($0.01)||$14.70 million||$15.40 million||View||N/A|
|11/6/2014||Q314||$0.04||$0.04||$15.60 million||$15.30 million||View||N/A|
|8/11/2014||Q114||$0.06||$0.09||$14.90 million||$15.60 million||View||N/A|
|5/8/2014||Q1||$0.07||$0.13||$15.14 million||$16.33 million||View||Listen|
|3/6/2014||Q413||$0.14||$0.10||$15.88 million||$10.40 million||View||Listen|
|11/7/2013||Q313||$0.13||$0.18||$16.27 million||$18.80 million||View||Listen|
|8/1/2013||Q2 2013||$0.10||$0.14||$15.97 million||$17.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.07||$12.82 million||$16.46 million||View||Listen|
|11/8/2012||Q312||$0.06||$8.63 million||$15.10 million||View||N/A|
Earnings Estimates for Repligen Corporation (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.55
2018 EPS Consensus Estimate: $0.73
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Repligen Corporation (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Repligen Corporation (NASDAQ:RGEN)
Insider Ownership Percentage: 1.50%Insider Trades by Quarter for Repligen Corporation (NASDAQ:RGEN)
Institutional Ownership Percentage: 96.45%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/21/2017||Karen A Dawes||Director||Sell||2,521||$34.12||$86,016.52|| |
|3/20/2017||Howard Benjamin||VP||Sell||12,216||$34.62||$422,917.92|| |
|3/20/2017||Thomas F Ryan Jr||Director||Sell||4,000||$34.83||$139,320.00|| |
|3/17/2017||Jon Snodgres||CFO||Sell||1,909||$34.91||$66,643.19|| |
|11/28/2016||Anthony Hunt||CEO||Sell||5,000||$33.12||$165,600.00|| |
|9/14/2016||Thomas F Ryan Jr||Director||Sell||2,700||$32.58||$87,966.00|| |
|6/30/2016||Thomas F Ryan Jr||Director||Sell||5,000||$26.60||$133,000.00|| |
|6/28/2016||Thomas F Ryan Jr||Director||Sell||10,000||$24.59||$245,900.00|| |
|5/11/2016||Howard Benjamin||VP||Sell||2,889||$26.72||$77,194.08|| |
|6/9/2015||Howard Benjamin||VP||Sell||35,000||$38.14||$1,334,900.00|| |
|5/11/2015||Walter C Herlihy||CEO||Sell||104,569||$37.94||$3,967,347.86|| |
|5/8/2015||Thomas F Ryan Jr||Director||Sell||20,000||$37.19||$743,800.00|| |
|3/23/2015||Walter C Herlihy||CEO||Sell||24,536||$31.78||$779,754.08|| |
|3/19/2015||James R Rusche||SVP||Sell||14,650||$33.30||$487,845.00|| |
|3/19/2015||Thomas F Ryan Jr||Director||Sell||10,000||$32.62||$326,200.00|| |
|3/19/2015||Walter C Herlihy||CEO||Sell||49,695||$33.08||$1,643,910.60|| |
|3/18/2015||Howard Benjamin||VP||Sell||15,795||$32.63||$515,390.85|| |
|11/19/2014||Walter C Herlihy||CEO||Sell||51,386||$23.43||$1,203,973.98|| |
|11/13/2014||Thomas F Ryan Jr||Director||Sell||10,000||$23.81||$238,100.00|| |
|11/11/2014||Howard Benjamin||VP||Sell||30,000||$23.56||$706,800.00|| |
|11/10/2014||Michael A Griffith||Director||Sell||23,342||$22.90||$534,531.80|| |
|8/13/2014||Howard Benjamin||VP||Sell||40,000||$20.34||$813,600.00|| |
|6/27/2014||Thomas F Ryan Jr||Director||Sell||10,000||$22.41||$224,100.00|| |
|6/24/2014||Thomas F Ryan Jr||Director||Sell||10,000||$21.78||$217,800.00|| |
|6/11/2014||Walter C Herlihy||CEO||Sell||60,335||$20.11||$1,213,336.85|| |
|6/9/2014||James R Rusche||SVP||Sell||30,000||$20.19||$605,700.00|| |
|6/6/2014||Daniel P Witt||SVP||Sell||47,709||$20.56||$980,897.04|| |
|4/15/2014||Daniel P Witt||SVP||Buy||10,000||$3.05||$30,500.00|| |
|8/8/2013||James R Rusche||SVP||Sell||30,000||$10.01||$300,300.00|| |
|6/21/2013||Karen A Dawes||Director||Buy||1,000||$7.70||$7,700.00|| |
|5/17/2013||Thomas F Ryan Jr||Director||Sell||21,000||$8.97||$188,370.00|| |
|5/15/2013||Thomas F Ryan Jr||Director||Sell||86,039||$9.01||$775,211.39|| |
|5/15/2013||Walter C Herlihy||CEO||Sell||40,000||$8.97||$358,800.00|| |
|9/21/2012||Glenn L Md Cooper||Director||Buy||10,000||$6.09||$60,900.00|| |
|8/16/2012||Michael A Griffith||Director||Buy||2,000||$4.88||$9,760.00|| |
Headline Trends for Repligen Corporation (NASDAQ:RGEN)
Latest Headlines for Repligen Corporation (NASDAQ:RGEN)
Repligen Corporation (RGEN) Chart for Saturday, October, 21, 2017